Drug intelligence / Profile preview

KN-069

Development stage: Phase 1
Lead developer: Suzhou Alphamab Co., Ltd.
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

KN-069 is a monoclonal antibody under development for the treatment of obesity and metabolic diseases. It is being developed by Suzhou Alphamab (also known as Alphamab Oncology) and Xiamen Amoytop Biotech. The drug is currently in Phase 1 clinical trials in China, where it is being evaluated for safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity in overweight or obese male participants. The precise mechanism of action has not been disclosed as of the latest updates[1][2][3][4]. It is administered subcutaneously.

Beyond the preview

Go deeper on KN-069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN-069.

Explore the full profile